NewKerala.com

Indian Pharma Soars in 2025: PMBJP, PLI & PRIP Schemes Drive Major Growth

The Indian pharmaceutical industry achieved significant milestones in 2025, driven by key government initiatives. The Pradhan Mantri Bhartiya Janaushadhi Pariyojana expanded to over 17,600 centers, providing massive cost savings to citizens. The Production Linked Incentive scheme far exceeded investment targets and boosted exports of high-value drugs. Additionally, the Promotion of Research and Innovation scheme and a successful Medtech Expo reinforced India's position as a global innovation hub.

Key Points: 2025 Pharma Growth: PMBJP, PLI, PRIP Schemes Boost Industry

  • 2,202 new Jan Aushadhi Kendras opened in 2025
  • PLI scheme generated over Rs 3 lakh crore in sales
  • PRIP scheme approved 111 research projects
  • India Medtech Expo 2025 showcased innovation hub
2 min read

PMBJP, PLI, PRIP scheme major boosts to Indian pharma industry in 2025: Govt

Indian pharma sees major 2025 growth with PMBJP, PLI, and PRIP schemes, achieving record sales, exports, and massive citizen savings.

"In 2024-25, the PMBI registered sales of Rs 2,022.47 crore, which led to savings of approximately Rs 8,000 crore to the citizens - Ministry of Chemicals and Fertilisers"

New Delhi, Jan 6

The Indian pharma industry in 2025 saw a major leap with the government's flagship Pradhan Mantri Bhartiya Janaushadhi Pariyojana, and schemes like the Production Linked Incentive and Promotion of Research and Innovation in Pharma Medtech Sector, the government said on Tuesday.

In an official statement, the Ministry of Chemicals and Fertilisers stated that under the PMBJP, 2,202 Jan Aushadhi Kendras (JAKs) were opened in 2025, taking the total number to 17,610 since launch.

These centres, implemented through the Pharmaceuticals & Medical Devices Bureau of India (PMBI), provide generic versions of branded medicines at affordable prices.

The PMBJP comprises 2,110 medicines, and 315 medical devices and consumables covering 29 therapeutic groups such as anti-infectives, anti-diabetics, cardiovascular, anti-cancers, gastro-intestinal medicines, etc.

"In 2024-25, the PMBI registered sales of Rs 2,022.47 crore, which led to savings of approximately Rs 8,000 crore to the citizens," the ministry said.

"In the current financial year 2025-26, till November, the PMBI has made sales of Rs 1,409.32 crore, which has led to savings of approximately Rs 5,637 crore to the citizens," it added.

The PLI Scheme for pharmaceuticals supports the manufacturing of high-value products like biopharmaceuticals, complex generics, patented/off-patent drugs, orphan, and autoimmune drugs.

"It generated a total sale of Rs 3,08,408.60 crore, including Rs 1,98,509.49 crore in exports since inception till September 2025," the statement said.

Further, investment worth Rs 40,294 crore has also been made under the scheme till September 2025. The amount significantly exceeded the targeted investment of Rs 17,275 crore.

The PLI scheme for the promotion of domestic manufacturing also helped reduce the import dependence for bulk drugs.

"Thirty per cent of India's overall bulk drug exports and 26.5 per cent of overall formulation exports in FY 2025 have been contributed through production under the scheme," the statement said.

Under the PRIP Scheme, 111 research projects were approved.

Other major initiatives and achievements of the ministry in 2025 include the success of India Medtech Expo 2025, which showcased the end-to-end MedTech ecosystem in the country.

It also reinforced India's position as a global MedTech innovation hub.

Further, the National Institutes of Pharmaceutical Education and Research (NIPERs) continue to enhance medical education.

The NIPERs were ranked among the top 30 pharmacy institutes in the country, with 40 of its faculty members figuring in the prestigious Stanford Top 2 per cent Scientists List.

- IANS

Share this article:

Reader Comments

A
Arjun K
The export numbers under PLI are staggering! Over 3 lakh crore in sales? This is how we build Atmanirbhar Bharat. Reducing import dependence for bulk drugs is crucial for our long-term health security. Kudos to all the scientists and manufacturers involved.
R
Rohit P
Good news, but the ground reality is sometimes different. The Jan Aushadhi store in my town often runs out of stock for common medicines. The scheme is excellent, but supply chain and distribution need equal focus to truly benefit every citizen.
D
David E
As someone working in the medtech sector, the PRIP scheme and the focus on research is the most exciting part. 111 projects approved! India has the brainpower; we just need the right funding and ecosystem. The Stanford list mention for NIPER faculty is impressive.
S
Shreya B
Rs 8000 crore saved by citizens? That's massive. Imagine that money staying in the pockets of common people. This is genuine public welfare. Hope they expand the list of medicines and devices even further.
K
Karthik V
The investment exceeding target by more than double shows the confidence of the industry. When policy is clear and incentives are aligned, private capital will follow. Now we need to ensure the quality of these generic medicines is never compromised. That trust is everything.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50